Seeking Alpha

Novartis' (NVS -1.1%) approved Gilenya treatment cut brain volume loss in multiple sclerosis...

Novartis' (NVS -1.1%) approved Gilenya treatment cut brain volume loss in multiple sclerosis patients by a third vs a comparator and a placebo and in three large Phase III trials. Brain volume loss is an important indicator of disease progression; data also shows that Gilenya consistently reduces relapse rates across disease activity. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)